Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Research from University of Connecticut provides new data on melanoma
May 14th, 2008
" To assess the antitumor activity of vitespen (autologous, tumor-derived heat shock protein gp96 peptide complexes) by determining whether patients with stage IV melanoma treated with vitespen experienced longer overall survival than patients treated with physician's choice. Patients and Methods Patients (N=322) were randomly assigned 2:1 to receive vitespen or physician's choice (PC) of a treatment containing one or more of the following: dacarbazine, temozolomide, interleukin-2, or complete tumor resection," researchers in the United States report. "This open-label trial was conducted at 71 centers worldwide. Patients were monitored for safety and overall survival. ...
Source: Vaccine Weekly (2008-05-14)
|
